Latest Commercialization News

Pilot Energy has initiated a formal farmout process to attract partners for its offshore Perth Basin permit WA-481P, featuring the ready-to-drill Leander Gas Prospect with 1.1 trillion cubic feet of prospective gas resources.

Aerometrex has completed a strategic review that delivers $2 million in cost savings and initiates data monetisation, positioning the company for accelerated growth in FY26.

Macarthur Minerals has updated its rights issue prospectus, introducing a cap on the underwriter's shareholding and revising key offer terms. These changes aim to balance funding needs with shareholder control and regulatory compliance.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Lithium Plus Minerals reports key regulatory and environmental milestones for its Lei Lithium Development Project, progressing towards a near-term direct shipped ore operation backed by a strategic partnership with Canmax Technologies.

Elsight Limited has raised A$60 million through a strongly supported placement, marking a milestone with consecutive record revenues and cash flow breakeven. The company is poised to capitalize on surging defence budgets and expanding drone markets with a robust pipeline of opportunities.

Elsight Limited reports record-breaking revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market opportunities, positioning the company for profitability later this year.

Elsight Limited reports a record 340% revenue surge to US$4.8 million in the first half of 2025, backed by a robust US$11.45 million contract backlog and a strategic A$60 million capital raise to fuel expansion.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

FleetPartners delivered a resilient 3Q25 performance with 5% growth in key metrics despite operational challenges from a major system upgrade. A recent $400 million asset-backed securitisation deal also improved funding costs, positioning the company for growth in underpenetrated markets.

Structural Monitoring Systems Plc (SMS) reported a breakout second half of FY25 with a $3.1 million profit after tax, driven by strong operational leverage and strategic growth in avionics. The company secured over US$1 million in new orders from CAL FIRE and advanced FAA certification for its innovative sensor technology.